All News
Filter News
Found 512 articles
-
US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine
5/23/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review a New Drug Application (NDA) for zavegepant nasal spray.
-
Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
5/23/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole, in patients with spinocerebellar ataxia (SCA).
-
Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery
5/17/2022
Sosei Group Corporation, the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor targets with a goal of creating new drug discovery programs in the area of gastrointestinal diseases.
-
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2022
5/13/2022
Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2022.
-
Pfizer made the splash of the young week Tuesday morning, inking an acquisition deal with New Haven, Connecticut-based Biohaven Pharma totaling $11.6 billion.
-
Biohaven Reports First Quarter 2022 Financial Results and Reports Recent Business Developments
5/10/2022
Biohaven Pharmaceutical Holding Company Ltd. reported financial results for the first quarter ended March 31, 2022, and provided a review of recent accomplishments during and anticipated upcoming milestones.
-
Pfizer to Acquire Biohaven Pharmaceuticals
5/10/2022
Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.
-
Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022
5/9/2022
Biohaven Pharmaceutical Holding Company Ltd. plans to hold its upcoming first quarter 2022 earnings call and webcast, reporting financial results for the quarter ended March 31, 2022, and provide a review of recent accomplishments and anticipated upcoming milestones, on Wednesday, May 11, 2022 at 8:30 a.m. ET.
-
Pfizer Reports First-Quarter 2022 Results
5/3/2022
Pfizer Inc. reported strong financial results for first-quarter 2022 and updated certain components of 2022 financial guidance.
-
Since its $63 billion acquisition of Allergan in 2019, AbbVie has become one of the leading companies developing therapies for migraine.
-
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
4/27/2022
Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced that the European Commission has granted marketing authorization for VYDURA®, a calcitonin gene-related peptide receptor antagonist for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month.
-
Sosei Heptares to Embed Agile Operating Model and Enhance its Translational Medicine Capabilities through Strategic Collaboration with Weatherden
4/26/2022
Sosei Group Corporation announces a strategic collaboration with Weatherden, a pioneering clinical development consulting group.
-
Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directorse
4/22/2022
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced the appointment of Amrit Ray, M.D., M.B.A. to the company’s Board of Directors.
-
Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update
4/14/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced two updates regarding Nurtec® ODT (rimegepant), the only FDA-approved medication to both treat and prevent migraine attacks in adults.
-
Biohaven Real-World Study Highlights Increased Healthcare Utilization Among Americans with Episodic Migraine having Higher Levels of Migraine-Related Disability
4/14/2022
Biohaven Pharmaceutical Holding Company Ltd. announced the publication of new real-world research showing that as migraine-related disability increases, healthcare utilization also increases among Americans with episodic migraine.
-
Osmol Therapeutics Announces Closing of Series A-1 Funding to Advance the Clinical Development of the First Therapy to Prevent Chemotherapy-Induced Neuropathy
4/12/2022
Osmol Therapeutics today announced that it has closed the first $5.2 million tranche of a $7.5 million Series A-1 financing led by Koax Investment Partners.
-
The American Academy of Neurology Annual Meeting (AAN) was held virtually and in-person in Seattle from April 2-7. Here’s a look at some of the highlights.
-
Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec® ODT Therapy: A Real-World Administrative Claims Analysis
4/7/2022
Biohaven announced the presentation of important findings pertaining to the benefit of Nurtec® ODT (rimegepant) in decreasing the burden of opioid use among a significant number of migraine patients in real world clinical practice.
-
Nurtec (rimegepant) Lactation Clinical Study Published in Breastfeeding Medicine Journal
4/1/2022
Biohaven Pharmaceutical Holding Company Ltd., announced that data from a Phase 1, single-center, open-label study evaluating the excretion of a single dose of rimegepant 75 mg in the human milk of healthy lactating women was published in the peer-reviewed journal, Breastfeeding Medicine, the official journal of the Academy of Breastfeeding Medicine.
-
Biohaven Data at 2022 American Academy of Neurology (AAN) Annual Meeting Demonstrate Leadership in Migraine and Commitment to Advancing Potential New Therapeutic Options in Neurological Diseases
3/31/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 13 abstracts, including two oral presentations, will be featured at the 2022 American Academy of Neurology (AAN) annual meeting being held April 2-7 in Seattle, WA and virtually from April 24-26.